Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Humabs BioMed

Humabs BioMed?uq=kzBhZRuG
2004 FOUNDED
M&A STATUS
1-10 EMPLOYEES
M&A LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Developer of human monoclonal antibodies created to treat a wide range of serious infections in the human body. The company's human monoclonal antibodies have passed natural selection by the human immune system in response to viral and bacterial diseases, in addition it also developes anti-infective immunotherapies for the traetment of induce protective and therapeutic immune responses which solutions are non-existent or inadequate, enabling patients and pharmaceutical companies to get drugs for the treatment of rare diseases.

Website
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Drug Discovery
Biotechnology
Parent Company
Primary Office
  • Via Mirasole 1
  • 6500 Bellinzona
  • Switzerland

+41 091 000 00 00

Humabs BioMed Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Humabs BioMed‘s full profile, request access.

Request full access to PitchBook

Humabs BioMed Executive Team (3)

Name Title Board
Seat
Contact
Info
Filippo Riva Managing Director, Chief Financial Officer and Chief Executive Officer
Davide Corti Ph.D Senior Vice President and Chief Scientific Officer
Nadia Passini Ph.D Director of Research and Development Operations and Translational Science